Trump taps Scott Gottlieb lead FDA

Drug Administration. Dr. Gottlieb served as FDA deputy commissioner for Medical and scientific events in 2005-2007, during the George W. Bush administration.

He's currently a practicing doctor and fellow at the American Enterprise Institute (AEI), a nonprofit dedicated to investigate and Education on issues of government, economics and social wellbeing.

In accordance with Politico he's a prolific writer on health care problems, Especially the pharmaceutical market. He is Regarded as a strong Supporter of this industry, and it has championed deregulation.

While Trump has promised in various times to make fairly radical changes At the FDA, Dr. Gottlieb is a regarded as a conventional option to get Commissioner by a Republican president.

Before his tenure as FDA deputy commissioner, Dr. Gottlieb functioned as a Senior advisor to FDA Commissioner Mark McClellan from 2003-2004, and since That the FDA's director of health policy enhancement. He abandoned FDA in the Spring of 2004 to work on implementation of this new Medicare Drug Benefit Being a senior advisor to the Administrator of both Medicare and Medicaid Services, in which he supported the agency's policy work Quality advancement and coverage and payment decision-making, Especially linked to new healthcare engineering.

Dr. Gottlieb is the author of more than 300 articles that have appeared In leading medical journals as well as The Wall Street Journal, The York He has held editorial positions On the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on CNBC.

Steve Mister, president and CEO of the Council for Responsible Nutrition (CRN), Washington, D.C., noted that Dr. Gottlieb was at the FDA when The industry embraced Adverse Event Reporting (AER) requirements. The Fact that he has a history and a brief history together with FDA means he knows What it requires to conduct the agency. “Industry likes predictability,” Mr. Mister said.

It remains to be seen how he may balance the need for governmental Oversight/regulatory enforcement and industry's own efforts to self-regulate.